• Malignant brain tumors are rare and understudied
  • Survival for gliomas has not improved in 30 years
  • Ohio is a stronghold of individual brain tumor investigators, novel neuro-oncology, basic science and clinical research
  • We can now study the genetic changes responsible for the onset, spread and recurrence of brain tumors
  • Multi-Institutional Clinically Annotated Biospecimen Resource


Phase II study of Radioimmunotherapy with Zevalin® (Ibritumomab Tiuxetan) Therapy for Patients with Refractory or Relapsed Primary Central Nervous System Lymphoma (Studychair: Ahluwalia)

A Prospective Phase II Trial of NovoTTF-100A with Bevacizumab (Avastin) in Patients with Recurrent Glioblastoma (Study chair: Ahluwalia)


  • Access the innovation of our clinicians and researchers
  • Clinical trials in other cancers– including both Adult and Pediatric studies in
  • Oncology
  • Facilitated multi-site scientific review
  • Reliant IRB – IRB “HUB”
  • Collaborative correlative studies with researchers across the state


 Established State-Wide  Multi-Institution, Multi-Disciplinary Neuro-oncology Research Team
  • Ohio Brain Tumor Study
  • Central Brain Tumor Registry of the United States
  • The Cancer Genome Atlas
  • Gliogene, An International Brain Tumor Family Study


The Case Comprehensive Cancer Center (Case CCC) is an NCI-designated Comprehensive Cancer Center. Our consortium brings together the best and brightest research faculty of its partner institutions, Case Western Reserve University, University Hospitals Case Medical Center and Cleveland Clinic. Located in Cleveland, Ohio, the Case CCC serves a population with higher than average cancer rates. Our researchers dedicate themselves to improving cancer outcomes through basic studies into signaling pathways giving rise to cancer and its genetic and epigenetic causes, pursuing novel therapeutic targets, and analyzing lifestyle interventions to prevent cancer and detect it earlier.

We are proud to be one of only 41 NCI-designated Comprehensive Cancer Centers in the nation. To learn more about our Center, please visit our website at


  • Improve the prevention, diagnosis and therapy of cancer through discovery, evaluation and dissemination.
  • Stimulate and support innovative, coordinated interdisciplinary clinical research on cancer diagnosis, treatment, prevention and control.
  • Develop clinical applications of discovery and make these available to Northern Ohio residents as quickly as possible through the integrated efforts of the major health systems in the region.
  • Develop cancer prevention and control activities that build on the expertise of the Center and result in a reduction of cancer morbidity and mortality in Northern Ohio and the nation.

The research efforts of the Case CCC members are organized into eight interdisciplinary scientific programs. The clinical research effort is supported by 12 Clinical Trials Disease Teams that develop and prioritize clinical trials, and a single Protocol Review and Monitoring System, Data Safety and Monitoring Plan integrate cancer research, cancer therapeutics, and prevention services at the partner institutions and throughout the region. Dr. Gerson is currently the Cancer Center Director.

Research programs of the Case CCC are also extending into community medical centers operated by University Hospitals and Cleveland Clinic. Outreach programs for clinical practice-based prevention and screening initiatives, educational programs, minority recruitment, and facilitation of patient referrals are also supported by the partner institutions.